Tandem Diabetes Care (Nasdaq:TNDM) announced real-world data confirming positive outcomes with its t:slim X2 insulin pump. Data demonstrated that the t:slim X2 pump with Control-IQ advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management. According to a news release, the […]
Auto-injectors
Study results show improved time in range with Diabeloop automated insulin delivery system
Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system. Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia. According […]
Study supports use of PharmaJet’s needle-free vaccine delivery systems
PharmaJet announced today that study data demonstrated increased immunogenicity when using its needle-free delivery system. Golden, Colorado-based PharmaJet presented the research results for the needle-free vaccine injection technology last week at the World Vaccine Congress. PharmaJet’s needle-free systems have been incorporated into clinical studies for multiple RNA and DNA vaccine and therapeutic development programs thanks […]
Study shows sustained improvements with Medtronic’s MiniMed 780G with Guardian 4
Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona. Data demonstrated sustained improvements in […]
Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
Comera inks deal with Intas to reformulate infusion treatments into one-shot self-injections
Comera Life Sciences announced that it will collaborate with Intas Pharmaceuticals to develop a new generation of biologic medicines. Woburn, Massachusetts-based Comera will develop a differentiated formulation of an Intas product using its SQore formulation platform, while Ahmedabad, India-based Intas will provide research funding with the option to acquire global rights to the formulation through […]
How Insulet created its next-gen Omnipod 5
Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January. Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery […]
Koru Medical names former Fresenius Kabi VP as chief technology officer
Koru Medical Systems (Nasdaq:KRMD) announced that it appointed medtech veteran Brian Case as its new chief technology officer (CTO). With more than 20 years of experience in medtech R&D, Case joins after spending more than 16 years at Fresenius Kabi as VP of R&D. Before Fresenius Kabi, he served as an R&D program manager for […]
Lyra Therapeutics closes $100.5M private placement
Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million. The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares […]